Novo Nordisk's ZEUS Null Result: A €8 Billion Question Mark Over the Cardiovascular Strategy
Published on 08/01/2026 at 16:22 | Redaktion boerse-global.de
The arithmetic of drug development can be brutally simple. A single hazard ratio of 0.99 — a number that statistically means the treatment performed no better than placebo — erased roughly €8 billion in market value from Novo Nordisk's balance sheet on Friday. The Danish pharmaceutical giant's shares tumbled 8.48 percent to close at €40.90 in German trading, marking the steepest single-day decline in nearly five months and leaving the stock 25.45 percent below its January peak of €54.86.
What makes the ZEUS failure particularly galling for the company is that the drug did exactly what it was designed to do biologically — and still came up empty clinically. Ziltivekimab, an interleukin-6 inhibitor acquired through the 2020 takeover of Corvidia Therapeutics for $725 million plus up to $2.1 billion in potential milestone payments, reliably suppressed free IL-6 and high-sensitivity C-reactive protein in the more than 6,300 patients enrolled in the Phase 3 trial. Those patients, all suffering from atherosclerotic cardiovascular disease, chronic kidney disease, and systemic inflammation, received monthly 15-milligram doses. Yet when the data were tallied against the primary composite endpoint of cardiovascular death, non-fatal heart attack, and stroke, the 95 percent confidence interval of 0.88 to 1.11 told an unambiguous story: no statistically significant risk reduction.
The news lands at an awkward moment for a company whose strategic narrative has increasingly leaned on diversification beyond its GLP-1 franchise. Ziltivekimab was meant to be the credible growth pillar outside the fiercely contested obesity and diabetes arena — a hedge against the intensifying US pricing pressure and Eli Lilly's competitive encroachment on Wegovy and Ozempic. With that option now shelved, Novo Nordisk's dependence on its blockbuster metabolic drugs has become more pronounced than ever.
Martin Holst Lange, the company's chief scientific officer, acknowledged the disappointment while insisting the cardiology commitment remains intact. That stance is backed by action: two additional Phase 3 trials, HERMES in heart failure and ARTEMIS in post-acute myocardial infarction patients, continue to run, with readouts expected in the first half of 2027. A successful result in either could still rehabilitate the program.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
For the current fiscal year, management has confirmed the 2026 guidance stands unaffected, though the third quarter will carry a non-cash impairment charge tied to the ZEUS study. The market's reaction, however, suggests investors are looking past the accounting mechanics. Jefferies and Citi analysts both characterized Friday's sell-off as overdone while conceding the strategic damage is real. The broader analyst consensus currently sits at "Hold" with a price target near $47.
The technical picture offers a more nuanced read. Friday's close of €40.90 placed the shares precisely on their 50-day moving average, while remaining 1.35 percent above the 200-day average of €40.35 — evidence that the medium-term uptrend has been dented but not destroyed. Still, the stock is down roughly seven percent year-to-date, and the annualized 30-day volatility of 35.80 percent reflects a market braced for further headlines from Copenhagen. The relative strength index at 41.8 suggests the sell-off has not yet reached oversold territory.
There are other moving parts beyond the failed trial. The oral Wegovy pill and a higher-dose 7.2-milligram version secured EU approval in mid-July, and late in the month Novo Nordisk filed suit against Eli Lilly over allegedly misleading advertising for its GLP-1 products. A share buyback program of up to $2.3 billion is underway, with roughly $1.10 billion deployed as of July 24.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
All of this converges on August 5, when Novo Nordisk reports second-quarter earnings. Consensus estimates point to earnings per share of $0.81, a 16.5 percent decline year over year, while alternative projections model revenue of 71.5 billion Danish kroner and EPS of 5.04 kroner — both below prior-year levels. The report will offer the first clear read on whether the GLP-1 engine can carry the valuation alone, or whether the ZEUS setback marks the beginning of a more prolonged de-rating.
Ad
Novo Nordisk Stock: New Analysis - 1 August
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
